Cofetuzumab pelidotin (PF-06647020) is a PTK7-targeting ADC comprising a humanized anti-PTK7 mAb (hu6M024, IgG1) joined to an auristatin microtubule inhibitor payload, auristatin-0101 (Aur0101; HY-12522), by a cleavable valine-citrulline (vc)-based linker. Cofetuzumab pelidotin has a DAR of 4. It has average molecular weight of 151.7KDa. Cofetuzumab pelidotin binds to cell-surface PTK7 with an EC50 of 1153 pM by flow cytometry. Cofetuzumab pelidotin has the potential for solid tumors research. This product is for research use only.
Product Details |
Species Reactivity | Human |
---|
Type | Antibody-drug conjugate |
---|
ADC antibody | anti-PTK7 mAb (hu6M024, IgG1) |
---|
ADC cytotoxin (drug) | Dxd |
---|
Immunogen | protein tyrosine kinase 7 |
---|
DAR (Drug to Antibody Ratio) | ~4 |
---|
Purity | 99% |
---|
Molecular Weight | 151.7kDa |
---|
Protein Concentration | 10mg/ml |
---|
Storage Condition | Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
---|
Storage Buffer | PBS buffer pH7.4 |